Cell 2 presented a good initial response against EGFR inhibitors, but the occurrence of the two PIK3CA pathogenic variants could be translated into the later acquisition of resistance to treatment, as described in metastatic colorectal cancer [71]. This evidence concerns the gene PIK3CA and metastatic colorectal cancer.